Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Cytokinetics Inc (NASDAQ: CYTK) closed the day trading at $37.50 down -6.69% from the previous closing price of $40.19. In other words, the price has decreased by -$6.69 from its previous closing price. On the day, 2.5 million shares were traded. CYTK stock price reached its highest trading level at $41.075 during the session, while it also had its lowest trading level at $37.46.
Ratios:
For a better understanding of CYTK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on February 07, 2025, initiated with a Buy rating and assigned the stock a target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.
On November 08, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $80.RBC Capital Mkts initiated its Outperform rating on November 08, 2024, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 31 ’25 when Blum Robert I sold 15,000 shares for $40.75 per share. The transaction valued at 611,250 led to the insider holds 427,629 shares of the business.
Malik Fady Ibraham sold 2,000 shares of CYTK for $87,160 on Mar 18 ’25. The EVP Research & Development now owns 140,455 shares after completing the transaction at $43.58 per share. On Mar 17 ’25, another insider, Callos Andrew, who serves as the EVP, Chief Commercial Officer of the company, sold 2,775 shares for $44.38 each. As a result, the insider received 123,154 and left with 34,888 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4440412672 and an Enterprise Value of 4287567872. For the stock, the TTM Price-to-Sale (P/S) ratio is 240.41. Its current Enterprise Value per Revenue stands at 232.087 whereas that against EBITDA is -8.14.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.94, which has changed by -0.47123522 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $75.71, while it has fallen to a 52-week low of $39.81. The 50-Day Moving Average of the stock is -17.52%, while the 200-Day Moving Average is calculated to be -26.97%.
Shares Statistics:
Over the past 3-months, CYTK traded about 1.63M shares per day on average, while over the past 10 days, CYTK traded about 1982220 shares per day. A total of 118.21M shares are outstanding, with a floating share count of 115.43M. Insiders hold about 2.52% of the company’s shares, while institutions hold 109.79% stake in the company. Shares short for CYTK as of 1741910400 were 14220519 with a Short Ratio of 8.74, compared to 1739491200 on 15069465. Therefore, it implies a Short% of Shares Outstanding of 14220519 and a Short% of Float of 18.290001.
